Clinical application of MRD in acute myelogenous leukemia bywt1 quantitative combined with FCM
10.19405/j.cnki.issn1000-1492.2017.03.019
- VernacularTitle:wt1定量联合FCM在急性髓细胞白血病MRD监测中的临床应用
- Author:
Yingchan HAO
;
Xiucai XU
- Keywords:
wt1 gene;
acute leukemia;
real time quantitative polymerase chainreaction;
multiparameter flow cytometry;
minimal residual disease
- From:
Acta Universitatis Medicinalis Anhui
2017;52(3):392-396
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the clinical application of minimal residual disease in acute myelogenous leukemia(AML) by wt1 mRNA quantitative combined with multi-parameter flow cytometry (FCM).Methods Real time quantitative polymerase chain reaction (qRT-PCR) method was established for detecting wt1 gene expression level in 35 AML patients.The indexes were detected by different subtypes;And 9 cases of ease and 4 cases of recurrence in patients was followed-up and detected the wt1 level.The multiparameter flow cytometry was used to analyze the minimal residual disease in AML.Results The expression of wt1 gene was significantly higher than that of the control group.Significant difference was found(P<0.05).In the newly diagnosed AMLs, wt1 was the highest in M2 and the lowest in M6.Follow-up of 4 AML patients showed that wt1 gene expression level was markedly decreased after CR, but obviously increased after relapse.The proportion of abnormal myeloid cells in different phases significantly changed by FCM.There was no difference of minimal residual disease in AML by qRT-PCR and multiparameter flow cytometry.The ROC curve was used to analyze the recurrent cases to get the threshold value(3.33%).Conclusion The quantitative analysis of wt1 combined with multi-parameter flow cytometry can be used to monitor minimal residual disease in leukemia patients, assess the treatment efficacy and prognosis, and predict the risk of recurrence.
